for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BIO-TECHNE Corp

TECH.OQ

Latest Trade

200.43USD

Change

2.93(+1.48%)

Volume

176,874

Today's Range

197.59

 - 

201.56

52 Week Range

132.75

 - 

217.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
197.50
Open
197.59
Volume
176,874
3M AVG Volume
3.50
Today's High
201.56
Today's Low
197.59
52 Week High
217.11
52 Week Low
132.75
Shares Out (MIL)
37.89
Market Cap (MIL)
7,483.75
Forward P/E
39.64
Dividend (Yield %)
0.65

Next Event

Bio-Techne Corp Annual Shareholders Meeting

Latest Developments

More

Bio-Techne Releases Fourth Quarter Fiscal 2019 Results

Bio-Techne Receives Approval To Offer The Exodx Prostate Intelliscore Test In New York State

Bio-Techne Acquires B-Mogen Biotechnologies Inc

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BIO-TECHNE Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.

Industry

Biotechnology & Drugs

Contact Info

614 McKinley Pl NE

+1.612.3798854

http://www.techne-corp.com/

Executive Leadership

Robert V. Baumgartner

Independent Chairman of the Board

Charles R. Kummeth

President, Chief Executive Officer, Director

James T. Hippel

Chief Financial Officer, Senior Vice President - Finance

Brenda S. Furlow

Senior Vice President, General Counsel, Secretary

David Eansor

Senior Vice President - Biotechnology

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.6K

2018

0.6K

2019

0.7K

2020(E)

0.8K
EPS (USD)

2017

3.720

2018

4.540

2019

4.510

2020(E)

4.983
Price To Earnings (TTM)
79.92
Price To Sales (TTM)
10.48
Price To Book (MRQ)
6.43
Price To Cash Flow (TTM)
42.95
Total Debt To Equity (MRQ)
43.34
LT Debt To Equity (MRQ)
42.27
Return on Investment (TTM)
5.83
Return on Equity (TTM)
5.53

Latest News

BRIEF-Roche Expands Partnership With Bio-Techne To Offer Drug Discovery Researchers New Chromogenic Detection Options For Mrna Ish Tissue Analysis

* ROCHE EXPANDS PARTNERSHIP WITH BIO-TECHNE TO OFFER DRUG DISCOVERY RESEARCHERS NEW CHROMOGENIC DETECTION OPTIONS FOR MRNA ISH TISSUE ANALYSIS

BRIEF-Bio-Techne Q3 GAAP Earnings Per Share $0.52

* Q3 EARNINGS PER SHARE VIEW $1.14 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Bio-Techne Q2 GAAP Earnings Per Share $1.29

* QTRLY GAAP EPS SAW A ONE-TIME BENEFIT OF $0.94 FROM TAX REFORM Source text for Eikon: Further company coverage:

BRIEF-Bio-Techne Acquires Atlanta Biologicals Inc

* BIO-TECHNE CORP - TRANSACTION IS FINANCED THROUGH AVAILABLE CASH ON HAND

BRIEF-Women In Bio announces that Alpna Seth joins Bio-Techne's board

* Women In Bio announces that Alpna Seth joins Bio-Techne's board of directors Source text for Eikon:

BRIEF-Bio-Techne releases Q1 adjusted earnings per share $0.90

* Q1 earnings per share view $0.88 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Bio-Techne adds two new directors to its board

* Bio-Techne adds two new directors to its board Source text for Eikon: Further company coverage:

BRIEF-Bio-Techne releases serological assay to detect Zika virus infections

* Bio-Techne releases a highly sensitive and specific serological assay to detect Zika virus infections

BRIEF-Bio-Techne acquires Trevigen Inc

* Bio-Techne Corp says transaction is financed through available cash on hand

BRIEF-Bio-Techne Corp & Bio-Techne has entered into an exclusive license agreement

* Bio-Techne Corp - Bio-Techne has entered into an exclusive license agreement with multiclonal therapeutics

BRIEF-Bio-Techne reports Q1 GAAP earnings per share $0.44

* Q1 earnings per share view $0.79 -- Thomson Reuters I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up